Doctors’ adherence to guidelines recommendations and glycaemic control in diabetic patients in Quetta, Pakistan: Findings from an observational study

Tabassum Saher1, Yaser Mohammed Al-Worafi2, Muhammad Nouman Iqbal3, Abdul Wahid1, Qaiser Iqbal4, Asad Khan1, Muhammad Atif5 and Nafees Ahmad*1

1Department of Pharmacy Practice, Faculty of Pharmacy and Health Sciences, University of Baluchistan, Quetta, Pakistan, 2Department of Clinical Sciences, College of Pharmacy, University of Science and Technology of Fujairah, Fujairah, United Arab Emirates, 3Sardarpur Rural Health Centre, Khanial, Pakistan, 4Department of Pharmaceutics, Faculty of Pharmacy and Health Sciences, University of Baluchistan, Quetta, Pakistan, 5Department of Pharmacy Practice, Faculty of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur, Pakistan

Background: Poor control of diabetes mellitus (DM) is partly attributed to doctors’ poor adherence to guidelines.

Objective: To evaluate doctors’ adherence to pharmacotherapeutic recommendations of DM management guidelines and factors associated with guidelines adherence and glycaemic control.

Methods: This prospective observational study included 30 doctors who were treating DM patients in their private clinics in Quetta, Pakistan. On visit 1, a total of 600 prescriptions written by 30 enrolled doctors (20 patients per doctor) were noted along with patients’ sociodemographic and clinical characteristics. American Diabetes Association guidelines was used as a reference. The prescriptions noted were judged for guidelines compliance. Of 600 enrolled patients, 450 patients (15 patients per doctor) were followed for one more visit and included in final analysis. Glycated hemoglobin (HbA1c) level noted one visit 2 was related with the respective prescription on visit 1. Data were analyzed by SPSS (version 23). A p-value <0.05 was considered statistically significant.

Results: Patients received a median of two antidiabetic drugs (range: 1–5). A total of 73.1% patients were on polytherapy. Metformin was the most frequently prescribed (88.4%) antidiabetic followed by gliptins (46.2%). A total of 41.6% prescriptions were judged guidelines compliant. In multivariate binary logistic regressions (MVBLR) analysis, chronic kidney disease (CKD) (OR = 0.422) and polytherapy (OR = 0.367) had statistically significant negative associations (p-value <0.05) with guidelines’ compliant prescriptions. The group of doctors comprised of specialists and consultants wrote significantly (p-value = 0.004) high number of guidelines adherent prescriptions (mean rank = 20.25) than the group comprised of medical officers (mean rank = 11.34).
Introduction

Diabetes mellitus (DM) characterized by hyperglycemia is a chronic, complex metabolic syndrome resulting from either lack of insulin release, insulin resistance or both (1). According to International Diabetes Federation (IDF), it is one of the fastest growing global health emergencies. In 2021, approximately 537 million people were living with DM (2) and 6.5 million deaths in 20–79 years old people were attributed to DM and its complications (2). Despite its high prevalence and associated complications, glycemic control in diabetic patients is poor and ranges from 23.4 to 60% (3–6). In order to achieve the target glycemic levels and prevent and reduce complications of DM, a number of clinical practice guidelines have been published, regularly updated and widely disseminated by different organizations like IDF, the American Diabetes Association (ADA) etc., (7, 8). These guidelines contain recommendations based on high quality evidence obtained from large and rigorously conducted randomized control trials, individual patients’ data meta-analyses, systematic reviews and expert opinions (9, 10). Compliance with these guidelines have resulted in optimal glycemic control and preventing micro and macrovascular complications of DM (11–18). Nevertheless, a wide gap is present between guidelines recommendations and actual clinical practices (19–36). Non-pharmacological management contributes to optimal glycemic control, but pharmacotherapy is the most effective and commonly used medical intervention in treating DM. However, majority of the previously conducted studies have evaluated standards of diabetic care processes and targets (20, 29–35), and only few have examined doctors’ adherence to pharmacotherapeutic recommendations of guidelines. Studies which have assessed doctors’ adherence to pharmacotherapeutic recommendations of guidelines have done it by (i) evaluating anti-hyperglycemic prescription patterns and prescribing trends over time (24–28), (ii) review of patients’ medical records (15, 18, 20–23, 36) and (iii) assessing doctors’ knowledge about guidelines recommendations (19). These studies have certain worth mentioning limitations like lack of an explicit criterion to define doctor’s adherence to pharmacotherapeutic recommendations of guidelines (24–28), use of self-reported practices as a proxy of objective adherence to guidelines (19, 37) which are always subject to bias as doctors may overestimate their adherence to guidelines (38, 39), exclusion of patients with comorbidities, lack of detailed review of patient medical record to note that whether doctors’ non-adherence to guidelines was a justifiable one or not (20–22, 24–28, 37).

Unfortunately, Pakistan is one of those three countries (China, India and Pakistan) which not only harbors the largest number of diabetic patients but with estimated comparative prevalence of 33.6% in people of age 20–79 years, it currently ranks first globally. In order to evaluate and improve the standard of care provided to diabetic patients, it is necessary to assess the doctors’ adherence to guidelines. Due to scarcity of published information in this regard from Pakistan, and to overcome the abovementioned limitations associated with the previously conducted studies, this study was undertaken with the aim to evaluate the doctors adherence to pharmacotherapeutic recommendations of DM guidelines against an explicit criteria, factors associated with receiving guidelines compliant prescriptions and glycemic control.

Methods

Study design, settings, and population

This was an observational study conducted at private clinics in Quetta city from June 1, 2021 to December 31, 2021. After getting a written consent, a total of 30 doctors who were involved in treating diabetic patients were enrolled in the study. As we aimed to examine the prescriptions written by each enrolled doctor to a convenience sample of 15 established diabetic ambulatory patients, thus a total of 600 patients (20 patients were per the enrolled doctor) with a potential dropout rate of 25% were included in the study. Patients who were younger than 18 years, who were pregnant, asked to follow-up in <3 months
and did not come for the follow-up visit were excluded from the study.

**Data collection**

On the baseline visit, a purpose designed data collection form was used to collect patients’ sociodemographic, clinical and laboratory data from their medical records and if needed one-on-one interview with the patient. Diagnosis of DM and other concurrent clinical conditions were based in documentation in the patients’ medical record. Multiple concurrent clinical conditions like hypertension, dyslipidemia, chronic kidney diseases (CKD) etc., were noted and reported individually, whereas coronary heart diseases and heart failure were collectively categorized as cardiovascular diseases (CVD). Medicines prescribed were noted by their generic names. Treatment with antidiabetic medications with single active pharmaceutical ingredient (API) was termed as monotherapy, whereas, treatment with more than one API (either in fixed dose combination or two different individual drugs) was termed as multi-therapy. In order to find a reason for doctors’ justifiable non-adherence with guidelines recommendations, a detailed review of the patients’ medical records was carried out. Contraindications, adverse events and statement about ineffectiveness due to which the guidelines recommended drug is not prescribed, discontinued or changed were noted. A total of 450/600 enrolled patients (15 patients/enrolled doctor) were followed for one more visit. One the follow up visit which on average took 3.5 months, patients were tested for glycedated hemoglobin (HbA1c) and results were noted. Based on HbA1c values recommended by ADA guidelines (<7% in patients without any comorbidity and <8% in patients with comorbidity) patients were categorized into those having controlled and uncontrolled HbA1c. The criterion developed on the basis of ADA guidelines (Supplementary Chart 1) was used for assessing the doctors’ adherence to pharmacotherapeutic recommendations (7). A prescription was judged as guidelines’ compliant when:

i) ADA guidelines preferred first-line agent for the particular condition was prescribed.

ii) ADA guidelines preferred first-line agents with no contraindications to its use were prescribed to the patients with comorbidities.

iii) ADA guidelines preferred first-line agent for a particular condition was not prescribed due to adverse event supposedly caused by the preferred drug, contraindication or ineffectiveness.

Score of “1” and “0” were, guidelines’ adherent and non-adherent prescription.

**Data analysis**

Statistical Package for Social Sciences (SPSS v 23) was used for analyzing data. In order to find out factors associated with receiving guidelines compliant prescription and uncontrolled HbA1c, those variables which had a p-value (<0.20) in univariate analysis were entered into multivariate binary logistic regression analysis (MVBLRA). Furthermore, Mann-Whitney U and Kruskal Wallis tests wherever applicable were to observe difference between doctors’ demographics and guidelines adherence scores. A p-value <0.05 was considered statistically significant.

**Results**

The sociodemographic characteristics of enrolled doctors, and sociodemographic and clinical characteristics of 450 patients included in the final analysis are, respectively given in Tables 1, 2. The mean age of patients was 49.03 ± 11.87 years. Majority of them were males (61.3%), overweight (46.9%), had DM for >5 years (73.6%) and >2 comorbidities (43.1%) with hypertension being the most prevalent comorbidity (78.9%).

Patients received a median of 2 antidiabetic drugs (range: 1–5). Only 121 (26.9%) patients were on monotherapy. Among antidiabetics, metformin was the most commonly prescribed drug (88.4%) followed by glinptins (46.2%) (Table 3).

Out of 450 prescriptions, 187 (41.6%) were judged guidelines compliant. In multivariate analysis, suffering from CKD (OR = 0.422, p-value = 0.012) and polytherapy (OR = 0.367, p-value < 0.001) had statistically significant association with receiving guidelines’ compliant prescriptions. This model fit was based on non-significant Hosmer Lemeshow (p -value = 0.287) and overall percentage 65.3% from classification table (Table 4). On the basis of designation, doctors were divided
into two groups, that is, medical officers and others (specialists and consultants). Mann–Whitney U test revealed a significant difference ($U = 45.00$, $p$-value = 0.004) between the guidelines adherent practices by two groups. The group comprised of specialists and consultants wrote significantly high number of guidelines compliant therapies on the basis of doctors' gender, age, place of graduation and practice duration.

The mean HbA1c% values of patients on visit 1 and 2 were, respectively 9.2 ± 1.2 and 8.8 ± 1.6. Based on definition used in the current study, a total of 156 (36.7%) and 178 (39.5%) patients, respectively had controlled glycemic levels on visit 1 and 2. In multivariate analysis, suffering from dyslipidemia (OR = 0.134, $p$-value = 0.001), CKD (OR=0.111, $p$-value = 0.030) and receiving sulfonylureas (OR = 0.156, $p$-value = 0.001) and guidelines compliant prescription (OR = 4.195, $p$-value = 0.003) had statistically significant associations with controlled glycemic level on visit 2. This model fit was based on non-significant Hosmer Lemeshow ($p$-value = 0.612) and overall percentage 84.4% from classification table (Table 5).

### Discussion

Optimal glycemic control can significantly decrease the incidence of diabetic complications and enhance the patients’ expectancy and quality of life. Pharmacotherapy in compliance with clinical practice guidelines contributes in achieving optimal control of diabetes. In current study, only 41.6% prescriptions were in compliance with ADA guidelines recommendations (7). As mentioned above, there is a scarcity of published studies which have evaluated doctors' objective adherence to pharmacotherapeutic recommendations of DM guidelines by using explicit criteria and reviewing patients' medical records, this made it difficult for us to compare our findings with previously published studies. However, similar percentage (39%) of guidelines compliant therapy modification in diabetic patients has been reported by a study conducted in the United States (15).

On the other hand, a comparatively greater proportion (54.2%) of diabetic patients received guidelines’ compliant prescriptions in Turkey (22).

Unless contraindicated, ADA guidelines recommend metformin as a first-line anti-diabetic (7). Therefore, the high rate of metformin prescription in present study (88.4%) was in line with guidelines recommendations and studies conducted

### Table 2: Sociodemographic and clinical characteristics of patients.

| Variables                        | No. (%)       |
|----------------------------------|---------------|
| **Gender**                       |               |
| Male                             | 276 (61.3)    |
| Female                           | 174 (38.7)    |
| **Age (years)**                  |               |
| 25–30                            | 129 (28.7)    |
| 41–55                            | 168 (37.3)    |
| >55                              | 123 (34.0)    |
| **Body mass index (kg/m²)**      |               |
| Underweight (<18.5)              | 8 (1.8)       |
| Normal (18.5–24.9)               | 69 (15.3)     |
| Overweight (25.0–29.9)           | 231 (46.9)    |
| Obese (>30.0)                    | 162 (36.0)    |
| **Duration of diabetes mellitus**|               |
| <1 year                          | 11 (2.4)      |
| 1–5 year                         | 108 (24.0)    |
| >5 year                          | 331 (73.6)    |
| **Family history of cardiovascular diseases** | 295 (65.6)       |
| No                               | 180 (40.0)    |
| 1–2                              | 76 (16.9)     |
| >2                               | 194 (43.1)    |
| **Type of comorbidity**          |               |
| Stroke                           | 49 (10.1)     |
| Hypertension                     | 355 (78.9)    |
| Dyslipidemia                     | 245 (54.4)    |
| Cardiovascular disease           | 114 (25.3)    |
| Heart failure                    | 20 (4.4)      |
| Coronary heart disease           | 97 (21.6)     |
| Chronic kidney disease           | 86 (19.1)     |
| Stage-III a (eGFR = 45–59 ml/min/1.73 m²) | 33 |
| Stage-III b (eGFR = 45–59 ml/min/1.73 m²) | 17 |
| Stage-IV (eGFR = 15–29 ml/min/1.73 m²) | 11 |
| Stage-V (eGFR <15 ml/min/1.73 m²) | 4 |
| Stage unknown                    | 21            |
| Others                           | 110 (24.4)    |

eGFR, estimated glomerular filtration rate; min, minute; ml, milliliter; m, meter.

### Table 3: Prescription of antidiabetics.

| Variables                        | No. (%)       |
|----------------------------------|---------------|
| **Number of antidiabetics**      |               |
| prescribed                       |               |
| 1                                | 121 (26.9)    |
| 2–3                              | 124 (49.8)    |
| >3                               | 105 (23.3)    |
| **Antidiabetics prescribed**     |               |
| Metformin                        | 398 (88.4)    |
| DDP4 inhibitors                  | 208 (46.2)    |
| Insulin                          | 177 (39.3)    |
| Sulfonylureas                    | 150 (33.3)    |
| SGLT-2 inhibitors                | 74 (16.4)     |
| GLPRA                            | 9 (2.0)       |

DDP4, Dipeptidyl peptidase-4; GLPRA, Glucagon-like Peptide-1 receptors agonists; SGLT2, Sodium-glucose cotransporters-2.
TABLE 4 Factors associated with receiving guidelines compliant prescriptions.

| Variables                | Guidelines compliant Rx No. (%) | Univariate analysis | Multivariate analysis |
|--------------------------|--------------------------------|---------------------|-----------------------|
|                          |                                | OR (95%CI)          | p-value               | OR (95%CI)          | p-value               |
|                          |                                |                     |                       |                     |                       |
| **Gender**               |                                |                     |                       |                     |                       |
| Male                     | 113 (40.9)                     | Referent            |                       |                       |                       |
| Female                   | 74 (42.5)                      | 1.067 (0.727–1.568) | 0.739                 |                       |                       |
| **Old age**              |                                |                     |                       |                       |                       |
| No                       | 145 (44.5)                     | Referent            |                       |                       |                       |
| Yes                      | 42 (33.9)                      | 0.639 (0.415–0.984) | 0.042                 | 1.379 (0.767–2.479)  | 0.284                 |
| **Body mass index (kg/m²)** |                          |                     |                       |                       |                       |
| Underweight (<18.5)      | 2 (25.0)                       | Referent            |                       |                       |                       |
| Normal (18.5–24.9)       | 32 (46.4)                      | 2.595 (0.489–13.766)| 0.263                 |                       |                       |
| Overweight (25.0–29.9)   | 97 (46.0)                      | 2.553 (0.504–12.938)| 0.258                 |                       |                       |
| Obese (≥30.0)            | 56 (34.6)                      | 1.585 (0.310–8.111) | 0.580                 |                       |                       |
| **Comorbidities**        |                                |                     |                       |                       |                       |
| No                       | 86 (47.8)                      | Referent            |                       |                       |                       |
| 1–2                      | 35 (46.1)                      | 0.933 (0.545–1.597) | 0.801                 | 1.301 (0.729–2.323)  | 0.374                 |
| >2                       | 66 (34.0)                      | 0.564 (0.371–0.855) | 0.007                 | 1.500 (0.756–2.974)  | 0.246                 |
| **Hypertension**         |                                |                     |                       |                       |                       |
| No                       | 43 (45.3)                      | Referent            |                       |                       |                       |
| Yes                      | 144 (40.0)                     | 0.825 (0.523–1.302) | 0.409                 |                       |                       |
| **Dyslipidemia**         |                                |                     |                       |                       |                       |
| No                       | 92 (44.9)                      | Referent            |                       |                       |                       |
| Yes                      | 95 (38.0)                      | 0.778 (0.534–1.134) | 0.191                 |                       |                       |
| **Chronic kidney diseases** |                              |                     |                       |                       |                       |
| No                       | 165 (45.3)                     | Referent            |                       |                       |                       |
| Yes                      | 22 (25.6)                      | 0.415 (0.245–0.702) | 0.001                 | 0.422 (0.214–0.830)  | 0.012                 |
| **Cardiovascular diseases** |                             |                     |                       |                       |                       |
| No                       | 150 (44.6)                     | Referent            |                       |                       |                       |
| Yes                      | 37 (32.5)                      | 0.596 (0.381–0.932) | 0.023                 | 0.849 (0.448–1.610)  | 0.617                 |
| **Stroke**               |                                |                     |                       |                       |                       |
| No                       | 175 (43.6)                     | Referent            |                       |                       |                       |
| Yes                      | 12 (24.5)                      | 0.419 (0.212–0.827) | 0.012                 | 0.506 (0.236–1.084)  | 0.080                 |
| **Other diseases**       |                                |                     |                       |                       |                       |
| No                       | 146 (42.9)                     | Referent            |                       |                       |                       |
| Yes                      | 41 (37.3)                      | 0.790 (0.507–1.229) | 0.295                 |                       |                       |
| **Type of therapy**      |                                |                     |                       |                       |                       |
| Monotherapy              | 72 (59.5)                      | Referent            |                       |                       |                       |
| Polymotherapy            | 115 (35.0)                     | 0.366 (0.238–0.561) | <0.001                | 0.367 (0.218–0.617)  | <0.001                |

CI, confidence interval; Kg/m², kilogram per square meter; OR, odds ratio; Rx, prescription.
*Old age (>55 years for males, > 65 years for females).

elsewhere (37, 40). Moreover, its extensive availability, low cost and being a component of fixed dose combinations (FDC) could have also contributed to high prescription rate of metformin. In current cohort, Dipeptidyl peptidase-4 inhibitors commonly known as gliptins were the second most commonly prescribed anti-diabetics and were received by 44.6% patients. Guidelines recommend that if in a diabetic patient without comorbidity, first-line therapy is insufficient to control blood glucose levels, any one of gliptins, thiazolidinediones, sulfonylureas and SGLT2-1 should be added as a second-line agent (7). Therefore, the relatively higher prescription rate of gliptins was compliant with guidelines recommendations and findings of studies conducted elsewhere (37, 41). The additional benefits of improved blood glucose control, cardio-protective effects, being weight neutral (42) and availability as FDC might be the other reasons for high prescription rates of gliptins.
TABLE 5 Factors associated with glycemic control.

| Variables                  | Glycemic control | Univariate analysis | Multivariate analysis |
|----------------------------|------------------|---------------------|-----------------------|
|                            | No. (%)          | OR (95% CI)         | p-value               | OR (95% CI) | p-value               |
| **Gender**                 |                  |                     |                       |            |                       |
| Male                       | 125 (45.3)       | Referent            |                       | 0.565 (0.276–1.163) | 0.121 |
| Female                     | 53 (30.5)        | 0.529 (0.355–0.790) | 0.002                 | Referent   |                       |
| **Old age**                |                  |                     |                       |            |                       |
| No                         | 162 (49.7)       | Referent            |                       | Referent   |                       |
| Yes                        | 16 (12.9)        | 0.150 (0.085–0.215) | <0.001                | Referent   | 0.481 (0.173–1.337)  | 0.161 |
| **Body mass index (kg/m²)**|                  |                     |                       |            |                       |
| Underweight (<18.5)        | 5 (62.5)         | Referent            |                       | Referent   |                       |
| Normal (18.5–24.9)         | 59 (85.5)        | 3.540 (0.729–17.195) | 0.117                 | Referent   | 1.135 (0.131–0.790)  | 0.909 |
| Overweight (25.0–29.9)     | 93 (44.1)        | 0.473 (0.110–2.030) | 0.314                 | Referent   | 0.414 (0.057–3.015)  | 0.384 |
| Obese (>30.0)              | 21 (13.0)        | 0.089 (0.020–0.402) | 0.002                 | Referent   | 0.446 (0.051–3.920)  | 0.467 |
| **Comorbidities**          |                  |                     |                       |            |                       |
| No                         | 128 (71.1)       | Referent            |                       | Referent   |                       |
| 1–2                        | 32 (42.1)        | 0.295 (0.169–0.516) | <0.001                | Referent   | 0.706 (0.205–2.431)  | 0.581 |
| >2                         | 18 (9.3)         | 0.042 (0.023–0.074) | <0.001                | Referent   | 0.274 (0.035–2.140)  | 0.217 |
| **Hypertension**           |                  |                     |                       |            |                       |
| No                         | 69 (72.6)        | Referent            |                       | Referent   |                       |
| Yes                        | 109 (30.7)       | 0.167 (0.101–0.276) | <0.001                | Referent   | 0.555 (0.227–1.360)  | 0.198 |
| **Dyslipidemia**           |                  |                     |                       |            |                       |
| No                         | 142 (69.3)       | Referent            |                       | Referent   |                       |
| Yes                        | 36 (31.6)        | 0.076 (0.048–0.121) | <0.001                | Referent   | 0.134 (0.040–0.454)  | 0.001 |
| **Chronic kidney diseases**|                  |                     |                       |            |                       |
| No                         | 175 (48.1)       | Referent            |                       | Referent   |                       |
| Yes                        | 3 (3.5)          | 0.039 (0.012–0.126) | <0.001                | Referent   | 0.111 (0.015–0.805)  | 0.030 |
| **Cardiovascular diseases**|                  |                     |                       |            |                       |
| No                         | 166 (49.4)       | Referent            |                       | Referent   |                       |
| Yes                        | 12 (10.5)        | 0.120 (0.064–0.227) | <0.001                | Referent   | 1.603 (0.377–6.812)  | 0.522 |
| **Stroke**                 |                  |                     |                       |            |                       |
| No                         | 175 (43.6)       | Referent            |                       | Referent   |                       |
| Yes                        | 3 (6.1)          | 0.084 (0.026–0.275) | <0.001                | Referent   | 0.758 (0.166–3.465)  | 0.720 |
| **Others**                 |                  |                     |                       |            |                       |
| No                         | 143 (42.1)       | Referent            |                       | Referent   |                       |
| Yes                        | 35 (31.6)        | 2.165 (1.235–3.798) | 0.007                 | Referent   | 1.401 (0.481–4.079)  | 0.536 |
| **Metformin**              |                  |                     |                       |            |                       |
| No                         | 10 (19.2)        | Referent            |                       | Referent   |                       |
| Yes                        | 168 (42.2)       | 3.068 (1.497–6.289) | 0.002                 | Referent   | 1.304 (0.289–5.886)  | 0.730 |
| **Sulfonylurea**           |                  |                     |                       |            |                       |
| No                         | 160 (53.3)       | Referent            |                       | Referent   |                       |
| Yes                        | 18 (12.2)        | 0.119 (0.069–0.205) | <0.001                | Referent   | 0.156 (0.052–0.566)  | 0.001 |
| **Insulin**                |                  |                     |                       |            |                       |
| No                         | 144 (72.5)       | Referent            |                       | Referent   |                       |
| Yes                        | 34 (19.2)        | 0.213 (0.137–0.332) | <0.001                | Referent   | 0.692 (0.305–1.569)  | 0.378 |
| **SGLT-2 inhibitors**      |                  |                     |                       |            |                       |
| No                         | 165 (43.9)       | Referent            |                       | Referent   |                       |
| Yes                        | 13 (17.6)        | 0.213 (0.137–0.332) | <0.001                | Referent   | 1.844 (0.506–0.6713) | 0.354 |

(Continued)
In current cohort, patients who suffered from CKD and received multiple anti-diabetics were significantly less likely to receive guidelines compliant prescriptions. Presence of comorbidities complicates management of diabetes and has previously been reported as a risk factor for guidelines divergent prescriptions (36, 43). Upon cross-tabulation, we found that 85/86 diabetic CKD patients were treated with two or more anti-diabetics. Of these 85 patients, 45 were on two and 40 on three antidiabetics. As per ADA guidelines, metformin is contraindicated in CKD patients with eGFR <30 ml/min/1.73 m², and in CKD patients of stage III-a and III-b who are already on metformin, the maximum daily doses of metformin should be reduced to 2,000 mg and 1,000 mg, respectively (7). We found that 9/15 patients with end-stage renal disease received the contraindicated metformin, and its dose was not adjusted in 30 patients with CKD stage III. It was also observed that 23/45 diabetic CKD patients who received two anti-diabetics were not on guidelines recommended second line agents i.e., SGLT2i or GLP1-RA (7). The higher odds of guidelines divergent prescriptions in CKD patients and those who received polytherapy show that doctors deviated from guidelines while selecting the correct doses and second line agents in these patients. Moreover, as diabetes is often treated as a ‘glucose centric disease’ (9), the incidence of adverse renal outcomes due to irrational doses and less preferred anti-diabetics might not have a preference of the current cohort of doctors. Similar doctors’ guidelines divergent practices among diabetic CKD patients have also been reported from Malaysia (23).

In current cohort, diabetes control was poor and only 39.5% patients were at goal glycemic level on visit 2. Likewise, in previously published studies glycemic control in diabetic patients ranged from 23.4 to 60% (3–6). In multivariate analysis, patients who suffered CKD, dyslipidemia and received sulfonylureas were significantly less likely to be at goal glycemic levels. Whereas, the odds of glycemic control was significantly higher in those who received guidelines compliant prescriptions. Due to metabolic acidosis, elevated levels of parathyroid hormone, and decreased level of vitamin D, early stages of CKD are associated with decreased production and resistance to insulin (44). As majority of diabetic CKD patients in current cohort had CKD stage-III, the significantly high prevalence of poor glycemic control in these patients is not astonishing. As glucose and lipid metabolism are interlinked to each other, many Type 2 diabetic patients usually suffer from dyslipidemia. Therefore, dyslipidemia is not only the consequence but also the cause of a disturbed glucose metabolism. It has been reported that elevated levels of triglycerides lead to elevated levels of free fatty acids which may induce insulin resistance and β-cell dysfunction, worsen glucose metabolism and make it more difficult to achieve glycemic goals in patients with hypertriglyceridemia (45). Similar finding of negative association between dyslipidemia and glycemic control have been reported by other studies conducted elsewhere (46, 47). In present study, patients who received sulfonylureas were significantly less likely to be at goal glycemic level. Sulfonylureas are potent hypoglycemic and reduce blood glucose levels by triggering insulin release from the pancreatic β-cells. However, by causing frequent episodes of hypoglycemia, progressive loss of effectiveness with chronic use and affecting cardiac potassium channels resulting in diminished response to ischemia, sulfonylureas are mostly used as third-line agents (48). Therefore, the current negative association between use of sulfonylureas and glycemic control could be due to their prescriptions to patients with severe

### TABLE 5 (Continued)

| Variables                  | Glycemic control | Univariate analysis | Multivariate analysis |
|----------------------------|------------------|---------------------|-----------------------|
|                            | No. (%)          | OR (95%CI)          | p-value               | OR (95%CI)          | p-value               |
| GLPRA                      |                  |                     |                       |                       |                       |
| No                         | 177 (40.1)       | Referent            |                       | Referent             |                       |
| Yes                        | 1 (11.1)         | 0.186 (0.023–1.504) | 0.115                 | 3.390 (0.161–71.225) | 0.432                 |
| Gliptins                   |                  |                     |                       |                       |                       |
| No                         | 98 (40.5)        | Referent            |                       | Referent             |                       |
| Yes                        | 80 (38.5)        | 0.918 (0.628–1.342) | 0.660                 |                       |                       |
| Type of therapy            |                  |                     |                       |                       |                       |
| Monotherapy                | 75 (62.0)        | Referent            |                       | Referent             |                       |
| Polytherapy                | 103 (31.3)       | 0.280 (0.181–0.342) | <0.001                | 1.301 (0.431–3.922)  | 0.641                 |
| Guidelines compliant Rx    |                  |                     |                       |                       |                       |
| No                         | 66 (25.1)        | Referent            |                       | Referent             |                       |
| Yes                        | 112 (59.9)       | 4.457 (2.976–6.676) | <0.001                | 4.195 (1.641–10.723) | 0.003                 |

CI, confidence interval; GLPRA, Glucagon-like Peptide-1 receptors agonists; Kg/m², kilogram per square meter; OR, odds ratio; Rx, prescription; SGLT2, Sodium-glucose cotransporters-2; *Old age (>55 years for males, ≥ 65 years for females).
diabetes. In current study, the likelihood of glycemic control was significantly greater in patients who received guidelines compliant prescriptions. Guidelines contain recommendations based on high quality evidence obtained from large and rigorously conducted randomized control trials, individual patients’ data meta-analyses, systematic reviews and expert opinions. Therefore, guidelines compliant practices should eventually benefit patients. Similar positive association between guidelines compliant therapy and glycemic control has been reported by studies conducted elsewhere (18). In current study, in terms of writing guidelines adherent prescriptions, specialists and consultants performed better than medical officers. Likewise findings have been reported by studies conducted elsewhere (39, 49). Comparatively high qualification, greater familiarity with guidelines recommendations and being in practice for longer periods could be the possible reasons for this finding.

**Conclusion**

Our findings demonstrate that both doctors’ adherence to pharmacotherapeutic recommendations of ADA guidelines and glycemic control were poor. Doctors mostly diverted from guidelines while prescribing to diabetic CKD patients and selecting the second line anti-diabetic agents. The finding that guidelines compliant pharmacotherapy resulted in better glycemic control reflects that remedial steps should be taken to improve guidelines adherence particularly in patients who were at greater risk of receiving guidelines non-compliant prescriptions. Availability of clinical pharmacists as a full member of diabetes care team, computerized decision support tools based on guidelines recommendations, dissemination of guidelines and behavior modeling by opinion leaders may improve doctors’ guideline adherence and patients’ glycemic control.

**Limitations**

This study has some notable limitations. Diabetic management is a multicomponent process involve screening, life-style modifications, pharmacological treatment and continued follow-up. However, the current study did not focus on overall diabetic care process but only evaluated doctors’ anti-diabetic prescribing practices. This study also lacks information about patients’ medication adherence. It did not evaluate the pharmacotherapeutic management of comorbidities like hypertension, dyslipidemia, CVD etc., and its impact on patients’ glycemic levels. Furthermore, DM is a chronic condition and requires a long observation period to decide about its control. Even though, to ensure that HbA1c level noted on final visit was the representative glycemic level of patients, we enrolled only established diabetic patients and excluded those whom follow-up visits were schedule in a span of <3 months.

**Data availability statement**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**Ethics statement**

The studies involving human participants were reviewed and approved by Ethical Institutional Review Board (IRB), Faculty of Pharmacy and Health Sciences, University of Balochistan, Quetta. The patients/participants provided their written informed consent to participate in this study.

**Author contributions**

TS, AW, and QI conceptualized the study. TS and AK collected the data. YMA and MNI analyzed the data. NA and MA wrote the manuscript. NA also supervised the study. All the authors contributed to the article and approved the submitted version.

**Acknowledgments**

We would like to acknowledge and give our warmest thanks to all the doctors and patients who made this work possible by becoming a part of this study.

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Supplementary material**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.978345/full#supplementary-material
Individualized HbA1c goals, and patient awareness and attainment of goals in adherence to evidence based guidelines in diabetes mellitus type 2, cardiovascular disease and prevention: a cross sectional study. BMC Fam Pract. (2013) 14:1-8. doi: 10.1186/1471-2296-14-47

21. Chan G. Type 2 diabetes mellitus with hypertension at primary healthcare level in Malaysia: are they managed according to guidelines? Singapore Med J. (2005) 46:127.

22. Satman I, Imamoglu S, Yilmaz C, Group AS. Adherence to guidelines and its effect on glycemic control during the management of type 2 diabetes in Turkey: the ADMIRE study. State Art Therap Endocrinol IntechOpen. (2012) 1:1294. doi:10.5772/15294

23. Iqbal MZ, Khan AH, Suleimana SA, Iqbal MS, Hussain Z. Guideline for adherence and diabetes control in co-morbid conditions in a tertiary hospital in Malaysia. Trop J Pharm Res. (2014) 13:1739. doi:10.4314/tjprr.v13i10.25

24. Curtis HJ, Dennis JM, Shields BM, Walker AJ, Bacon S, Hattersey AT et. al. Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017. Diabetes Obes Metab. (2018) 20:2159–68. doi:10.1111/dom.13346

25. Filon KB, Joseph L, Boivin JF, Suisse S, Brophy JM. Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis. Pharmacoeconomics Drug Saf (2009) 18:973-6. doi: 10.1080/13596800903320541

26. Ali Z, Imam SF, Adnan M, Shabbir I, Rahat I. Prescription pattern of antidiabetic drugs among type 2 diabetes patients of Sir Gang Ram Hospital, Lahore. Pak J Med Sci. (2015) 54:96.

27. Engler C, Leo M, Pfeifer B, Juchum M, Chen-Koeng S, Poeschl K et al. Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the diabetes registry tyrol 2012–2018. BMC Diabet Open Res Data. (2020) 8:e001279. doi:10.1186/s13079-020-001279

28. Azar ST, Malha LP, Zantout MS, Naj M, Younes E, Sawaya M-T. Management and control of patients with type 2 diabetes mellitus in Lebanon: results from the international diabetes management practices study (IDMPS). J Med Liban. (2013) 61:127–31. doi: 10.1186/00061439

29. Nawaz MS, Zafar HN, Saleem N, Naz M, Latif S, Usman M et al. Prevalence and prescribing trends of anti-diabetic drugs in type 2 diabetes mellitus according to standard treatment guidelines in different hospitals of Lahore. Pak J Pharm. (2018) 30:22–6. Available online at: https://doi.org/10.1111/pjph.12314

30. Linong J, Newman J, Juming L, Xiaoiling C. Understanding the standard of care in the treatment of type 2 diabetes in China: results from a national survey. Chin Med J. (2014) 127:3524–9. doi: 10.3760/cma.j.issn.0366-6999.2014.01008

31. Jabbar A, Hameed A, Chawla R, Akhter JJ. Understanding how well do Pakistan patients and physicians adhere to standards of diabetes care? Int J Diab Care. (2007) 27:93–6.

32. Satman I, Imamoglu S, Yilmaz C. Research ASGJD, practice c. A patient-based study on the adherence of physicians to guidelines for the management of type 2 diabetes in Turkey. Diabetes Res Clin Pract. (2012) 98:75-82. doi:10.1016/j.diabres.2012.05.003

33. Wesselin SFO, Linguma HH, Robben PB, Madderbrij JPBlhsr. Guideline adherence and health outcomes in diabetes mellitus type 2 patients: a cross-sectional study. BMJ Health Serv. (2015) 15:1–8. doi: 10.1136/bmjhsr-2014-000669-z

34. Albarak Al, Mohammmed R, Asseyr B, Ablam D, AI Morti S, AI Saleh R et al. Evaluation of diabetes care management in primary clinics based on the guidelines of American diabetes association. Int J Health Sci. (2012) 8:12–40. Available online at: https://pubmed.ncbi.nlm.nih.gov/28623016/

35. Srijiwatjiram A, Mounggern Y, Vannasea SJ. Outcome of American diabetes association clinical practice recommendations in 722 Thai type 2 diabetes patients. J Med Assoc Thai. (2011) 94: S159-S167. Available online at: https://www.thaisscience.info/Journals/Article/JMAT/10972110.pdf

36. Gabler M, Piner N, Geier S, Ley L, Aberle J, Lehrke M et al. Guideline adherence and associated outcomes in the treatment of type 2 diabetes mellitus patients with an incident cardiovascular comorbidity: an analysis based on a large German claims dataset. Diabetes Therapy. (2021) 12:1209–26. doi:10.1007/s13398-021-01024-y

37. Al-Zyoudi M, Al-Abdulaziz A, Al-Feek S, Al-hajajais A, Al-Sanarsi S et al. Prescribing patterns of antidiabetics in type 2 diabetes and factors affecting them. Saudi Pharm J. (2022) 30:112–9. doi:10.1016/j.jsps.2021.12.019

38. Adams AS, Soumerai SB, Lomas J, Ros-Degnan D. Evidence of self-report bias in assessing adherence to guidelines. Int J Qual Health Care. (1999) 11:187–92. doi:10.1093/intqhc/11.3.187
39. Ahmad N, Khan AH, Khan I, Khan A, Atif M. Doctors' knowledge of hypertension guidelines recommendations reflected in their practice. *Int J Hypertens.* (2018) 2018. doi: 10.1155/2018/8524063

40. Wang TY, Eguale T, Tamblyn R. Guidelines adherence in the treatment of patients with newly diagnosed type 2 diabetes: a historical cohort comparing the use of metformin in Quebec pre and post-Canadian diabetes Association guidelines. *BMC Health Serv.* (2013) 13:1–7. doi: 10.1186/1472-6963-13-442

41. Overbeek JA, Heintjes EM, Prieto-Alhambra D, Blin P, Lassalle R, Hall GC, et al. Type 2 diabetes mellitus treatment patterns across Europe: a population-based multi-database study. *Clin Ther.* (2017) 39:759–70. doi: 10.1016/j.clinthera.2017.02.008

42. Scheon AJ. Cardiovascular effects of gliptins. *Nat Rev Cardiol.* (2015) 10:63–73. doi: 10.1038/nrcardio.2012.183

43. Sales AE, Tipton EF, Levine DA, Houston TK, Kim Y, Allison J, et al. Are comorbidities associated with guideline adherence? The MI-Plus study of Medicare patients. *J Gen Intern Med.* (2009) 24:1205–10. doi: 10.1007/s11606-009-1096-4

44. Nasri H, Rafieian-Kopaei M. Diabetes mellitus and renal failure: Prevention and management. *J Res Med Sci.* (2015) 20:1112–20. doi: 10.4103/1735-1995.172845

45. Briaud I, Harmon JS, Kelpe CL, Segu VBG, Postiout V. Lipotoxicity of the pancreatic β-cell is associated with glucose-dependent esterification of fatty acids into neutral lipids. *Diabetes.* (2001) 50:315–21. doi: 10.2337/diabetes.50.2.315

46. Achila OO, Ghebreteinsae M, Kidane A, Simon M, Makonen S, Rezene Y. Factors associated with poor glycemic and lipid levels in ambulatory diabetes mellitus type 2 patients in Asmara, Eritrea: a cross-sectional study. *J Diabetes Res.* (2020) 2020:12. doi: 10.1155/2020/5901569

47. Khattab M, Khader YS, Al-Khawaldeh A, Ajlouni K. Factors associated with poor glycemic control among patients with type 2 diabetes. *J Diabetes Complicat.* (2010) 24:84–9. doi: 10.1016/j.jdiacomp.2008.12.008

48. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. *Drugs.* (2004) 64:1339–58. doi: 10.2165/00003495-200464120-00006

49. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. *JAMA.* (1999) 282:1458–65.